The DOI matches its Crossref record; 9 of the 9 references it cites were found in a registry or an index.
Niacin Increases HDL by Reducing Hepatic Expression and Plasma Levels of Cholesteryl Ester Transfer Protein in APOE*3Leiden.CETP Mice
Open accessAbstract
Objective— Niacin potently decreases plasma triglycerides and LDL-cholesterol. In addition, niacin is the most potent HDL-cholesterol–increasing drug used in the clinic. In the present study, we aimed at elucidation of the mechanism underlying its HDL-raising effect. Methods and Results— In APOE*3Leiden transgenic mice expressing the human CETP transgene, niacin dose-dependently decreased plasma triglycerides (up to −77%, P <0.001) and total cholesterol (up to -66%, P <0.001). Concomitantly, niacin dose-dependently increased HDL-cholesterol (up to +87%, P <0.001), plasma apoAI (up to +72%, P <0.001), as well as the HDL particle size. In contrast, in APOE*3Leiden mice, not expressing CETP, niacin also decreased total cholesterol and triglycerides but did not increase HDL-cholesterol. In fact, in APOE*3Leiden.CETP mice, niacin dose-dependently decreased the hepatic expression of CETP (up to −88%; P <0.01) as well as plasma CETP mass (up to −45%, P <0.001) and CETP activity (up to −52%, P <0.001). Additionally, niacin dose-dependently decreased the clearance of apoAI from plasma and reduced the uptake of apoAI by the kidneys (up to −90%, P <0.01). Conclusion— Niacin markedly increases HDL-cholesterol in APOE*3Leiden.CETP mice by reducing CETP activity, as related to lower hepatic CETP expression and a reduced plasma (V)LDL pool, and increases HDL-apoAI by decreasing the clearance of apoAI from plasma.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Intensive versus Moderate Lipid Lowering with Statins after Acute Coronary Syndromes
Cannon, C. P., Braunwald, E., McCabe, C. H., Rader, D. J., Rouleau, J. L., Belder, R., Joyal, S. V., Hill, K. A., Pfeffer, M. A., & Skene, A. M. (2004) · New England Journal of Medicine · doi:10.1056/nejmoa040583 · Cited by 4,938
Intensive Lipid Lowering with Atorvastatin in Patients with Stable Coronary Disease
LaRosa, J. C., Grundy, S. M., Waters, D. D., Shear, C., Barter, P., Fruchart, J.-C., Gotto, A. M., Greten, H., Kastelein, J. J. P., Shepherd, J., et al. (2005) · New England Journal of Medicine · doi:10.1056/nejmoa050461 · Cited by 3,489
Brown, B. G., Zhao, X.-Q., Chait, A., Fisher, L. D., Cheung, M. C., Morse, J. S., Dowdy, A. A., Marino, E. K., Bolson, E. L., Alaupovic, P., et al. (2001) · New England Journal of Medicine · doi:10.1056/nejmoa011090 · Cited by 1,979
High-Density Lipoprotein — The Clinical Implications of Recent Studies
Desforges, J. F., Gordon, D. J., & Rifkind, B. M. (1989) · New England Journal of Medicine · doi:10.1056/nejm198911093211907 · Cited by 1,547
Statins, high-density lipoprotein cholesterol, and regression of coronary atherosclerosis
Nicholls, S. J., Tuzcu, E. M., Sipahi, I., Grasso, A. W., Schoenhagen, P., Hu, T., Wolski, K., Crowe, T., Desai, M. Y., Hazen, S. L., et al. (2007) · JAMA · doi:10.1001/jama.297.5.499 · Cited by 724
High-Density Lipoprotein as a Therapeutic Target: A Systematic Review
Singh, I. M., Shishehbor, M. H., & Ansell, B. J. (2007) · JAMA · doi:10.1001/jama.298.7.786 · Cited by 468
Efficacy and safety of high-density lipoprotein cholesterol-increasing compounds
Birjmohun, R. S., Hutten, B. A., Kastelein, J. J. P., & Stroes, E. S. G. (2005) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2004.10.031 · Cited by 429
Mechanism of plasma cholesteryl ester transfer in hypertriglyceridemia.
Mann, C. J., Yen, F. T., Grant, A. M., & Bihain, B. E. (1991) · Journal of Clinical Investigation · doi:10.1172/jci115535 · Cited by 339
Cited by
Chapman, M. J., Le Goff, W., Guerin, M., & Kontush, A. (2010) · European Heart Journal · doi:10.1093/eurheartj/ehp399 · Cited by 298
Ali, K. M., Wonnerth, A., Huber, K., & Wojta, J. (2012) · British Journal of Pharmacology · doi:10.1111/j.1476-5381.2012.02081.x · Cited by 292
Braidy, N., Berg, J., Clement, J., Khorshidi, F., Poljak, A., Jayasena, T., Grant, R., & Sachdev, P. (2019) · Antioxidants & Redox Signaling · doi:10.1089/ars.2017.7269 · Cited by 275
Torres, N., Guevara-Cruz, M., Velázquez-Villegas, L. A., & Tovar, A. R. (2015) · Archives of Medical Research · doi:10.1016/j.arcmed.2015.05.010 · Cited by 273
G protein-coupled receptors for energy metabolites as new therapeutic targets
Blad, C. C., Tang, C., & Offermanns, S. (2012) · Nature Reviews Drug Discovery · doi:10.1038/nrd3777 · Cited by 273
Metadata
- Authors
- van der Hoorn, J. W. A., de Haan, W., Berbée, J. F. P., Havekes, L. M., Jukema, J. W., Rensen, P. C. N., & Princen, H. M. G.
- Venue
- Arteriosclerosis, Thrombosis, and Vascular Biology
- Published
- 2008-11
- Volume
- 28
- Issue
- 11
- Pages
- 2016-2022
- ISSN
- 1079-5642 (ISSN-L)
- 1524-4636
- OpenAlex
- W2160193200
- Cited by
- 173
- References
- 9
- FWCI
- 16.81
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Niacin Increases HDL by Reducing Hepatic Expression and Plasma Levels of Cholesteryl Ester Transfer Protein in APOE*3Leiden.CETP Mice. https://app.cochat.ai/papers/10.1161/atvbaha.108.171363
- The paper
- van der Hoorn, J. W. A., de Haan, W., Berbée, J. F. P., Havekes, L. M., Jukema, J. W., Rensen, P. C. N., & Princen, H. M. G. (2008). Niacin Increases HDL by Reducing Hepatic Expression and Plasma Levels of Cholesteryl Ester Transfer Protein in APOE*3Leiden.CETP Mice. Arteriosclerosis, Thrombosis, and Vascular Biology. https://doi.org/10.1161/atvbaha.108.171363
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.